We’ve entered a new paradigm of data-intensive drug discovery. A critical shortage of bioinformaticians, paired with an antiquated tech stack, threatens to stymie progress. What can today’s biotechnology leaders do to fully realize the potential of their bioinformatics teams?

The ability to acquire omics data has overtaken most labs’ capacity to analyze and gain insight from that data. At best, there is a bottleneck to analysis, and at worst, the data processing and analytics effort is paralyzed. What have we tried, and where can we go from here to transform data into insight?

While the explosion of multi-omics data holds great promise for accelerating drug discovery, its exponential growth in both size and variety has rapidly outpaced traditional informatics solutions. Existing tools offer either flexibility for bioinformaticians or usability for biologists - but until the development of a truly end-to-end bio-IT platform, never both.